08:00 , Dec 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Insulin-like growth factor 1 receptor (IGF1R; CD221); arrestin b1 (ARRB1); MAPK (ERK) Cell culture studies suggest inhibiting ARRB1 or ERK...
07:00 , Apr 7, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Arrestin b1 (ARRB1); ARRB2 In vitro and mouse studies suggest that inhibition of arrestin family proteins could help treat idiopathic pulmonary...
07:00 , Apr 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Dyslipidemia Arrestin b1 (ARRB1); G protein-coupled receptor 109A (GPR109A; HM74A) In vitro and mouse studies suggest that GPR109A agonists that...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) Arrestin b1 (ARRB1) In vitro and rat studies suggest that inhibiting ARRB1 could prevent hyperaldosteronism to...
08:00 , Feb 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Arrestin b1 (ARRb1); ARRb2; endothelin receptor type A (EDNRA; ETAR) A study in mice and in cell culture...